IHAT Featured as Sole EFSA-Evaluated Nanomaterial in NCF Magazine

NCF Magazine publication confirms “there is currently only one case of a nanomaterial proper that has been evaluated by EFSA for its safety, Iron Hydroxide Adipate Tartrate (IHAT)”

Nemysis Ltd. is pleased to announce that our innovative proprietary iron supplement, IHAT, has been featured in an article by Francesco Cubadda of the Italian National Institute of Health – ISS in the May 2025 issue of NCF International Magazine.

https://static.tecnichenuove.it/ncfinternational/2025/06/NCFW_01_NANOMATERIALS.pdf

In the article, Francesco Cubadda, provides a summary of the emerging field of assessing, approving and the ongoing monitoring of nanomaterials in food within Europe and specifically acknowledges IHAT as not only the first but the “only case of a nanomaterial proper that has been evaluated by EFSA for its safety”.

IHAT pioneered such assessment when it was independently evaluated by the European Food Safety Authority (EFSA) and was found to be safe both as a Novel Food (under Regulation (EU) 2015/2283) and as a source of iron (under Directive 2002/46/EC). EFSA’s positive opinion, published in December 2021, validated the safety and bioavailability of IHAT based on rigorous scientific evidence and supported its inclusion by the European Commission among the ingredients permitted for the production of food supplements (under Regulation (EU) 2024/248) on 17 June 2024.

The European framework and the work of EFSA in leading the governance and assessment of nanomaterials is import, opening the possibility of products such as IHAT, which was designed to mimic the natural nanostructure and absorption pathway of dietary ferritin, preventing the triggers adverse safety considerations and side effects common to all other iron supplement forms.

Nemysis Limited, as a small and entrepreneurial company focused on proprietary R&D, is proud to be the holder of the know-how, technology and rights to IHAT and, following its independent assessment as safe, to be working with distribution partners to commercialise IHAT, the first nanomaterial ever approved for use in food supplements in the EU.

Given the article’s recognition of IHAT’s unique position as the “only nanomaterial proper that has been evaluated by EFSA for its safety”, Nemysis takes this opportunity to thank the inventors, Dr. Comelli, Dr. Faria and Dr. Kessler for their commitment in the development and approval of IHAT, as well as the support of the EU, EFSA, the Joint Research Council and the network of national reference laboratories in pioneering the assessment and monitoring of this innovative and important category of materials within nutraceutical science and our other stakeholders.

Dr. Comelli commented “We are delighted with the results of the development and approval of IHAT and the role we can play in deploying the first and only approved nanomaterial technology for the betterment of health by addressing such prevalent conditions as iron deficiency and iron deficiency anaemia. It is never easy being ‘the first’, but we are grateful for the vision of the EU bodies and regulatory framework in supporting the appropriate safety assessment and monitoring of these important materials and feel rewarded that IHAT is already helping sufferers, particularly in the Women’s health space, to use this new technology to more safely and effectively replete their iron levels.”

 

Nemysis Limited Announces Investment by Avia Pharma AB in the Capital of the Company

DUBLIN, March 18, 2025 (Newswire.com) – Nemysis is pleased to announce signing of a Subscription Agreement (the “Agreement”) under which Avia Pharma AB has invested in the capital of the company. The proceeds from the issue of shares will be used to accelerate the commercialisation of the Company’s novel and innovative oral iron supplement, Iron Hydroxide Adipate Tartrate (“IHAT”), the Group’s wider commercial product portfolio and to support the completion of development and initial commercial manufacturing of Endoprotease 40, the Company’s oral enzymatic therapy for the destruction of Gluten and prevention of symptomatic gluten exposure in gluten intolerant (Celiac Disease) and non-celiac gluten sensitive sufferers.

This investment represents the first commitment under the Company’s current funding round as well as an important endorsement by a commercial company operating in the markets of Nemysis’ products and is expected to support ongoing funding discussions with private parties, as well as those resulting from the Grant First award secured by the Company under the EU’s Horizon programme. Commenting on the Agreement, Danilo Casadei Massari, Chairman & CEO remarks “We are delighted to have received this interest and support from Avia, a company with strong
experience operating in the markets our products target and therefore well positioned to appreciate their innovative nature and differentiated market positioning. Avia brings strong knowledge of the markets across Northern Europe, complementing our experience and expertise in the markets of Southern Europe.”

Jacob Calmvik, Avia Pharma AB CEO, states: “We are pleased to have invested in Nemysis and to be supporting the development and accelerated commercialisation of its important product portfolio which is in line with our aims of improving health in Northern Europe. Through our shared therapeutic areas of interest, we see great potential for ongoing and future collaborations as both a shareholder and stakeholder.”

About Avia Pharma AB

Avia Pharma AB is a Swedish pharmaceutical company with a focus on five therapy areas: women’s health, urology, dermatology, allergy and everyday healthcare across Northern Europe and in particular Finland, Sweden, Norway, Denmark, and Germany.

Avia Pharma AB
Birger Jarlsgatan 27
111 45 Stockholm

Aviapharma

Nemysis Limited Announces Collaboration With Avia Pharma AB as IHAT Distributor in Nordic Region

DUBLIN, March 14, 2025 (Newswire.com) – Nemysis is pleased to announce signing of a Distribution and Supply Agreement (the “Agreement”) for its unique oral iron supplement, Iron Hydroxide Adipate Tartrate (“IHAT”), with Avia Pharma AB (“Avia”), which will act as distributor.

Under the Agreement, Avia is appointed as the exclusive partner to Nemysis for the promotion, marketing, distribution and sale of Nemysis’ proprietary IHAT product under the Tolfer brand, under license.

Avia’s appointment is exclusive in Finland, Sweden, Norway and Denmark, as well as being semi-exclusive for Germany, where Avia is expanding its reach, including through the addition of IHAT to its product portfolio. This collaboration provides sufferers access to this important and revolutionary product for the safe and tolerable treatment of iron deficiency and iron deficiency anaemia, without the adverse risks.

This agreement marks a further strategic milestone for Nemysis and Avia, expanding the footprint of Tolfer outside its existing market of Italy, where IHAT has three distributors, and further strengthening the product portfolio of Avia with an innovative and differentiated product and the Tolfer brand.

Commenting on the Agreement, Marco Cartolari, Chief Operating Officer remarks “We are pleased to add this collection of territories to IHAT’s footprint and that of the Tolfer brand and to be working with a fast-growing partner such as Avia and its team. This collaboration is a robust strategic fit for both parties and we look forward to all stakeholders benefitting from Tolfer in the covered territories. ”

Fredrik Warstedt, Avia Pharma AB Head of M&A and Business Development, states: “We are excited to bring Tolfer into our product portfolio and by its prospects in our markets. We believe this unique product will support many of our customers and strengthen our ability to fulfil our mission of making Northern Europe a healthier place, particularly within our Women’s Health market focus.”

About iron deficiency

Iron deficiency and iron deficiency anaemia are the most widespread nutritional deficiency, affecting ~1.2 billion people globally, and are associated with a slew of symptoms, including tiredness, lack of energy, shortness of breath and, in more severe cases, an increased risk of serious morbidity and impaired immunity.

About IHAT

IHAT is a nanoparticulate ferric iron supplement that respects the physiology of natural iron. It was developed as an analogue of dietary ferritin, the natural iron storage protein, and follows its route of absorption. Like ferritin, IHAT is absorbed as whole nanoparticles in the intestine and does not release ‘free’ iron, a highly redox reactive form of iron and the culprit of the gastrointestinal side effects seen with conventional oral iron supplements. IHAT is efficacious and well-tolerated, with no negative impact on the gut microbiome.
About Avia Pharma AB

Avia Pharma AB is a Swedish pharmaceutical company with a focus on five therapy areas: women’s health, urology, dermatology, allergy and everyday healthcare across Northern Europe and in particular Finland, Sweden, Norway, Denmark, and Germany.

https://aviapharma.se/
Avia Pharma AB
Birger Jarlsgatan 27
111 45 Stockholm Sweden

Source: Nemysis Limited

Nemysis and EU Commission’s Joint Research Centre Apply Advanced Particle Size Analysis for IHAT

Press Release • updated: Nov 28, 2024 09:30 GMT

DUBLIN, November 28, 2024 (Newswire.com) – Nemysis is pleased to announce a significant outcome of its collaboration with the Joint Research Centre (JRC) of the European Commission. Their joint efforts have culminated in the publication of a study in the Journal of Food Composition and Analysis detailing the Member States’ interlaboratory testing of a co-developed dynamic light scattering (DLS) method for particle size analysis, specifically tailored for IHAT, Nemysis’ innovative iron-based nano-engineered novel food.

The collaboration aimed to further develop and apply Nemysis’ transferred analytical techniques for monitoring regulatory compliance of IHAT (primary particle nanosize: 2-5 nm). IHAT, approved by the EU Commission in 2023, is a safe and bioavailable iron source for food supplements designed to address iron deficiency and iron deficiency anaemia – one of the most widespread nutritional deficiencies globally, with particular significance in women’s health.

The co-developed Standard Operating Procedure will allow EU member states’ laboratories to assess compliance of IHAT – in bulk as well as in finished products – to the approved specification criteria. The study, led by Geiss et al., successfully demonstrated that dynamic light scattering can reliably measure particle size in the low nanometre range, if samples are prepared and measured following a robust, easy-to-reproduce, and standardised protocol.

Cristina Comelli, CSO of Nemysis Limited, commented:
“This publication is the culmination of a productive partnership with the JRC of the European Commission. It reflects our commitment to delivering safe, high-quality, and innovative solutions to improve human health.”

“IHAT represents a revolution in treating iron deficiency and iron deficiency anaemia, offering safer and more tolerable iron repletion compared to conventional oral iron supplements. This publication not only validates IHAT’s unique structure but also bolsters our efforts to bring this important product to the market” added Marco Cartolari, COO of Nemysis Limited.

About Tolfer (IHAT)

IHAT is a nanoparticulate ferric iron supplement that respects the physiology of natural iron. It was developed as an analogue of dietary ferritin, the natural iron storage protein which also has an iron nanoparticulate core, and follows ferritin’s route of absorption. Like ferritin, IHAT is absorbed as whole nanoparticles in the intestine and does not release ‘free’ iron, a highly redox reactive form of iron and the culprit of the gastrointestinal side effects seen with conventional oral iron supplements. IHAT is safe, efficacious and well-tolerated, with no adverse impact on the gut microbiome.

About Iron deficiency

Iron deficiency and iron deficiency anaemia are the most widespread nutritional deficiency, affecting ~1.2 billion people globally, and are associated with a slew of symptoms, including tiredness, lack of energy, shortness of breath and, in more severe cases, an increased risk of serious morbidity and impaired immunity.

Nemysis Limited Announces Completion of Acquisition in Italy

DUBLIN, November 5, 2024 (Newswire.com) – Nemysis Limited is pleased to announce the successful acquisition of TFarma SRL (“TFarma”) by its wholly-owned subsidiary, Enteralia Bioscience SRL (“Enteralia”).

TFarma is a leading distributor of specialized products with a strong focus on women’s health and gastroenterology, supported by a dedicated sales force of approximately 20 experienced representatives and managers. With its extensive network and deep industry expertise, TFarma is well-positioned to serve clinical communities across Italy.

This acquisition marks a transformative milestone for Enteralia, establishing a powerful sales and distribution platform in Italy, one of Europe’s largest healthcare markets. Enteralia will leverage this platform to accelerate the market introduction of Nemysis Group’s proprietary product pipeline, with a focus on its innovative IHAT nano-particulate oral iron therapy, which has received Novel Food approval from the European Union.

The synergies between Enteralia and TFarma in both target markets and commercial capability, along with planned investments in the combined business, enhance Nemysis Group’s strategy to deliver superior, differentiated healthcare solutions directly to Italian consumers.

“The acquisition of TFarma, with its strong expertise in women’s health and gastroenterological products, represents a pivotal step in Nemysis Group’s journey to becoming a fully integrated biopharmaceutical and healthcare organization. This acquisition supports our mission to combine exceptional international R&D with a robust commercial presence, bringing our innovative products directly to the Italian market,” said Danilo Casadei Massari, Chairman of Nemysis Limited.

Antonio Maggi, CEO of Enteralia Bioscience SRL, added, “The integration of TFarma’s proven sales and marketing capabilities with Enteralia’s proprietary product portfolio creates a unique platform focused on women’s health and gastroenterology. Through strategic investment in our commercial operations, we are excited to drive meaningful improvements in treatment options across our chosen fields.”

About Nemysis Limited
Nemysis Limited is a healthcare and pharmaceutical company focused on nutritional and pharmaceutical solutions designed to address nutrient deficiencies, intolerances, and sensitivities, with particular attention to protecting the human microbiome.

About Enteralia Bioscience
Enteralia Bioscience SRL, part of the Nemysis Limited group, is an Italian pharmaceutical company dedicated to expanding direct sales for the Nemysis Group’s product portfolio. This strategic initiative enhances Enteralia’s access to the value chain and reflects Nemysis’s evolution from a research-focused entity to a fully integrated biopharmaceutical company.

About TFarma SRL
TFarma SRL is an Italian pharmaceutical company with nearly 20 years of experience delivering innovative and effective solutions with a primary focus on women’s health and gastroenterological conditions.

 

Nemysis Limited Announces the Grant of Further IP for its IHAT Oral Iron Supplement

DUBLIN, May 23, 2024 (Newswire.com) – Nemysis is pleased to announce the further strengthening of its IP portfolio in relation to its unique and innovative nanoparticulate oral iron supplement, IHAT (Iron Hydroxide Adipate Tartrate), for the safe treatment of iron deficiency and iron deficiency anaemia.

The new patent (WO2021204705) was recently granted in Europe for the use of IHAT in the treatment and prevention of iron deficiency in liver disease, for which it is perfectly suited due to experimental and toxicological evidence of no iron overload in the liver from orally supplemented IHAT. This adds to the already robust Intellectual Property and Patent Protection of IHAT globally, including previous patents granted for other therapeutic uses, manufacturing and composition protection of IHAT and its development pipeline.

Together, these patents recognise and provide robust protection for IHAT as a unique, innovative and safe oral iron supplement relative to all other existing oral iron supplements.

Dr. Cristina Comelli, Chief Scientific Officer, remarks: “This newly granted patent protects the use of IHAT for the safe treatment and iron repletion in individuals with anaemia and underlying liver diseases. It specifically covers the application of IHAT in this therapeutic area, underscoring the importance of IHAT as the unique and safe nanoparticulate oral iron supplement and its ability to significantly improve the treatment and lives of those suffering from iron deficiency.”

Dr Nuno Faria, Chief Technical Officer, states: “Through the protection this patent provides for the specific use of IHAT in the safe treatment of iron deficiency in patients suffering liver diseases, combined with the broad protections of the existing patents related to IHAT, Nemysis holds robust protection for this revolutionary oral iron supplement, approved in a number of markets globally and currently being commercialised.”

About iron deficiency

Iron deficiency and iron deficiency anaemia are the most widespread nutritional deficiency, affecting ~1.2 billion people globally, and are associated with a slew of symptoms, including tiredness, lack of energy and shortness of breath and, in more severe cases, an increased risk of serious morbidity and impaired immunity.

About IHAT

IHAT is a nanoparticulate ferric iron supplement that respects the physiology of natural iron. It was developed as an analogue of dietary ferritin, the natural iron storage protein which also has an iron nanoparticulate core, and follows its route of absorption. Like ferritin, IHAT is absorbed as whole nanoparticles in the intestine and does not release ‘free’ iron, a highly redox reactive form of iron and the culprit of the gastrointestinal side effects seen with conventional oral iron supplements. IHAT is safe, efficacious and well-tolerated, with no adverse impact on the gut microbiome.

Source: Nemysis Limited

Nemysis Limited Signs With Kolinpharma SpA an IHAT Sales and Marketing Agreement

DUBLIN, January 10, 2024 (Newswire.com) – Nemysis Ltd and Kolinpharma® SpA (“Kolinpharma®”) are pleased to announce they have signed a non-exclusive sales and marketing agreement for IHAT (Iron Hydroxide Adipate Tartrate), Nemysis’ innovative oral iron supplementation product.

Under the agreement, Kolinpharma® will use its existing sales network and relationships with relevant clinical communities to market IHAT under its brand KIPFeR®. Concurrently, Nemysis intends to directly market IHAT under its brand, Tolfer, within Italy. Combined with Nemysis’ existing channels, this agreement will enhance coverage of the target markets within Italy, one of the largest in Europe.

Marco Cartolari, Nemysis’ COO, states: “We are pleased to partner with Kolinpharma and further expand our efforts to bring our cutting-edge oral iron supplementation product to a wider audience. By leveraging Kolinpharma’s specialist distribution network and expertise, we aim to ensure the broadest possible access to the latest and most effective solution for individuals suffering from iron deficiencies.”

“We are thrilled to partner with Nemysis and to have secured this distribution agreement for such an innovative oral iron supplementation product,” said Rita Paola Petrelli, Kolinpharma’s President. “This partnership allows us to expand our product portfolio and address the unmet needs of individuals with iron deficiencies and make a real difference in improving the health and well-being of countless patients.”

About iron deficiency

Iron deficiency and iron deficiency anemia are the most widespread nutritional deficiencies, affecting ~1.2 billion people globally, and are associated with a slew of symptoms, including tiredness, lack of energy, shortness of breath and, in more severe cases, an increased risk of serious morbidity and impaired immunity.

About IHAT

IHAT is a nanoparticulate ferric iron supplement that respects the physiology of natural iron. It was developed as an analogue of dietary ferritin, the natural iron storage protein, and follows its route of absorption. Like ferritin, IHAT is absorbed as whole nanoparticles in the intestine and does not release ‘free’ iron, a highly redox reactive form of iron and the culprit of the gastrointestinal side effects seen with conventional oral iron supplements. IHAT is efficacious and well-tolerated, with no negative impact on the gut microbiome.

About Nemysis Limited

NEMYSIS LTD, an Irish healthcare and pharmaceutical company, focuses on nutritional and pharmaceutical solutions to tackle Iron Deficiency/Anemia and Gluten Intolerance.

www.nemysisltd.com

About KOLINPHARMA® SpA

KOLINPHARMA® Spa, founded in 2013 and listed on the EGM market since March 2018, is an innovative SME operating in the nutraceutical market and specialized in Research and Development carried out both internally and in collaboration with the major Italian universities. KOLINPHARMA® products are made with innovative and natural raw materials and on the advice of the HCPs they aim to support pharmacological treatments mainly for pathologies in the orthopaedic-physiatric, urological-gynecological and neurological fields.

Product efficacy is validated by numerous scientific evidences, through the conduct of in vitro and clinical studies and publications in international scientific journals. The Company distributes its own branded products throughout Italy through a qualified network of over 90 Medical-Scientific Representatives (IMS). Internal R&D has allowed the registration of 46 patents, of which seven patents are in Italy, six in the USA, one in Israel and 32 patents in the main European countries. Kolinpharma also holds 13 certifications, of which nine on the company and three on the products. Furthermore, the products are free of gluten, milk, lactose and derivatives.

KOLINPHARMA S.p.A
Via Larga, 8
20122 Milan, Italy

Nemysis Limited Announces a Strategic Alliance With Bruno Farmaceutici S.p.A.

DUBLIN, November 8, 2023 (Newswire.com) – Nemysis is pleased to announce that it has entered into a Strategic Alliance Agreement (the “Agreement”) with Bruno Farmaceutici S.p.A. for the mutual advancement of the portfolio and sales of each company.

Nemysis Limited and Bruno Farmaceutici S.p.A. entered into the Agreement, under which both companies will cooperate on their strategic goals, and support the mutual development of their businesses, including through the expansion of their portfolios and international development. The alliance facilitates the mutual collaboration and provision of services, strengthening and broadening the capabilities of either company.

As part of the Agreement, Nemysis Limited grants Bruno Farmaceutici S.p.A. an option for a non-exclusive sales and marketing right for E40 within the Italian market, on terms to be agreed.

Danilo Casadei-Massari, Nemysis’ Chairman and CEO, states: “We are excited to be working with Bruno Farmaceutici S.p.A. for the mutual benefit of our businesses, and for the possibilities the joint capabilities and expertise will bring. We are also delighted by the interest shown in our E40 product, and the recognition of its commercial potential to address the gluten intolerance and sensitivity market. This agreement builds on the success of the option agreement entered into with Faran for the Greek market, earlier this year”.

Vincenzo Bruno, Chief Executive Officer of Bruno Farmaceutici S.p.A. remarks: “We are pleased to have partnered with an entrepreneurial and innovative company such as Nemysis Limited, and to be able to work with its team to strengthen our ability to source additional products for our portfolio, as well as identify opportunities for international expansion of our operations and our product portfolio. With the benefits that our Italian sales network and experience can bring to Nemysis, this agreement represents a great symbiotic opportunity for real strategic collaboration that will deliver tangible results”.

About E40

E40 is a recombinant protein for the degradation of gluten and its immunogenic peptides. It possesses all the required attributes to be an effective oral enzymatic therapy and act as a first-line treatment, whilst also demonstrating excellent safety, in particular as it is not systemically absorbed. As a medical device, E40 will be price-competitive and accessible, not requiring a medical prescription.

About Bruno Farmaceutici S.p.A.

Founded in 1996 as a spin-off from Aventis with a portfolio of medical specialities and a sales force of 42 medical representatives, Bruno Farmaceutici has grown its presence in the national market to become one of the most highly regarded pharmaceutical companies in Italy. Bruno Farmaceutici has steadily increased its turnover over the years to reach €110 million in 2022 and a sales force of over 120 medical representatives.

Source: Nemysis Limited

Nemysis Limited Receives EU Horizon Grant Funding for E40

DUBLIN, November 7, 2023 (Newswire.com) – Nemysis is pleased to announce receipt of grant funding under the European Horizon program, to advance the development of its E40 glutenase to Market Authorization for the management of gluten intolerance (celiac disease) and sensitivity.

https://eic.ec.europa.eu/system/files/2023-03/EIC%20Accelerator-January%2011%202023%20Cut%20Off.pdf

Following the company’s successful application, the EIC has awarded the maximum grant amount of €2.5m to fund the completion of research & development to Market Authorization of Nemysis’ novel Endoprotease 40 for the prevention of symptomatic gluten exposure in gluten intolerance and sensitivity. Also, through the “grant first” award, the company has the option to partner with the EIC for €6m of equity funding (matched by additional private investments), on terms to be agreed, to accelerate the commercialization of E40.

Dr. Cristina Comelli, R&D Director at Nemysis, commented, “We are thrilled to receive the EIC’s backing for our R&D strategy, aimed at introducing the inaugural product for celiac disease and gluten sensitivity to the market. This grant, together with additional resources, provides the financial means required to successfully conclude our development program, including toxicology studies and clinical trials, to secure E40’s approval as a Class IIb Medical Device, in Europe. Moreover, data generated from this program will play a key role in supporting E40’s regulatory pathway in the United States.”

Danilo Casadei-Massari, Chairman and CEO of Nemysis, remarks, “This award signifies the acknowledgement of Nemysis’ important contributions in addressing widespread unmet needs, extending beyond Europe. We eagerly look forward to advancing E40’s journey to market, courtesy of this grant, and the possibility for follow-on EIC equity funding to accelerate the global commercialization of E40.”

About gluten intolerance and sensitivity

Gluten intolerance (celiac disease) affects 1.4% of the global population, while gluten sensitivity, known as non-celiac gluten sensitivity, impacts approximately 7%. Both conditions manifest with a range of distressing symptoms, including diarrhea, fatigue, malabsorption, severe gastrointestinal issues, and a significant decline in quality of life. Currently, the sole management available is a challenging lifelong compliance with a Gluten-Free Diet. It’s noteworthy that as many as 30% of patients are unable to tolerate gluten levels even below the limit of 20 ppm of the GFD. Furthermore, 50% of calories in the Western diet derive from gluten-containing wheat, making inadvertent exposure commonplace. Therefore, the development of an effective complement to the Gluten-Free Diet, such as E40, addresses a crucial and widespread unmet need.

About E40

E40 is a recombinant protein for the degradation of gluten and its immunogenic peptides. It possesses all the required attributes to be an effective oral enzymatic therapy and act as a first-line treatment, whilst also demonstrating excellent safety, in particular, as it is not systemically absorbed. Taken before a meal, E40 has already been shown in the INFOGEST model to destroy gluten below the GFD threshold, preventing symptomatic exposure and abating the associated immune response. As a medical device, E40 will be price-competitive and accessible, not requiring a medical prescription.

Nemysis Limited Covered in Research Note

PRESS RELEASE • OCT 17, 2023 08:00 BST

DUBLIN, October 17, 2023 (Newswire.com) – Nemysis is pleased to announce that the company was recently covered by a research note published by The Life Sciences Division Limited (TLSD), a boutique investment bank based in London, specialising in the life sciences sector.

The note is accessible at: https://thelifesciencesdivision.com/research/portal/#/portal/the-life-sciences-division

The coverage raises the profile of the company and focuses on the potential of IHAT (Iron Hydroxide Adipate Tartrate), the company’s first product to receive market authorisation to date in Europe and Canada. The TLSD team’s research indicates the significant potential for IHAT and the company, subject to having sufficient financial resources to commercialise IHAT to its full potential.

The valuation ascribed to Nemysis supports Management’s strategy and vision for its key proprietary products, IHAT and E40, the company, its growth and the resultant forecast cash generation.

Danilo Casadei Massari, Nemysis’ Chairman and CEO, stated: “We are excited by this first research note on Nemysis, the assessment undertaken by TLSD and its alignment with our own expectations for the potential of IHAT and the Company, indicating a portfolio and commercial operation of significant value for our various stakeholders.”

Najma Pirzada, Head of Equity Capital Markets at TLSD, commented: “In evaluating a commercial-stage business such as Nemysis, careful consideration must be directed to market access, which Nemysis executive management has a track record in and demonstrated as a core competency through superior knowledge of local markets, sales and distribution. The opportunity to build a strong team to drive early revenues alongside a range of licensing deals is aggressively pursued by management. Additionally, Nemysis has the potential to rapidly progress R&D with Key Opinion Leaders driving the pipeline assets, a testament to the strength of their products”.

Dr. Navid Malik, Head of Research at TLSD, commented, “Nemysis’ products in the areas of Iron Deficiency Anaemia (IDA) and Celiac Disease target major markets with a need for such innovation to address significant underlying problems with existing treatments, or a lack thereof. Nemysis’ highly disruptive portfolio can address not only these markets but in the case of IHAT – major markets beyond, including Chronic Kidney Disease and Heart Failure, where a significant number of patients present with IDA at diagnosis. This demonstrates that successful innovation is transformative for small companies like Nemysis”.

About Nemysis Limited

NEMYSIS LTD, an Irish healthcare and pharmaceutical company, focuses on nutritional and pharmaceutical solutions to tackle Iron Deficiency/Anaemia and Gluten Intolerance.

nemysisltd.com

Nemysis Limited
Suite 4.01 Ormond Building 31-36 Ormond Quay Upper
Arran Quay, Dublin 7
D07 F6DC

About The Life Sciences Division

The Life Sciences Division (TLSD), based in London, is an independent investment bank providing advisory services to companies and investors in the life sciences sector, including corporate finance, corporate broking and corporate research.